Why differentiate low molecular weight heparins fo...[Thromb J. 2007] - PubMed Result

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 0

Click to change filter selection through MyNCBI.

1: Thromb J. 2007 Jun 19;5:8. Links

Why differentiate low molecular weight heparins for venous thromboembolism?

Fareed J, Walenga JM.

PMID: 17578577 [PubMed]

PMCID: PMC1936420

Related articles

ReviewAre all low molecular weight heparins equivalent in the management of venous thromboembolism?
Clin Appl Thromb Hemost. 2008 Oct; 14(4):385-92.

[Clin Appl Thromb Hemost. 2008]
ReviewLow-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review.
J Exp Clin Cancer Res. 2008 Jul 18; 27:21. Epub 2008 Jul 18.

[J Exp Clin Cancer Res. 2008]
ReviewPrevention of venous thromboembolism after ischemic stroke.
Curr Opin Pulm Med. 2008 Sep; 14(5):389-96.

[Curr Opin Pulm Med. 2008]
Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines.
Thromb J. 2008 Sep 9; 6:13. Epub 2008 Sep 9.

[Thromb J. 2008]
Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.
Thromb Res. 2008; 122(2):289-90; author reply 291. Epub 2008 Feb 21.

[Thromb Res. 2008]
» See reviews... | » See all...

Recent Activity

Clear Turn Off Turn On

Why differentiate low molecular weight heparins for venous thromboembolism?Why differentiate low molecular weight heparins for venous thromboembolism?

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show